Close
FINDING CURES TOGETHER<sup>SM</sup>

Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies

Program 

Thursday, Jan. 9

Friday, Jan. 10


Saturday, Jan. 11


Thursday, Jan. 9

Welcome and Opening Keynote Lectures
6:30-8:15 p.m.

Welcome
Elaine R. Mardis, Nationwide Children's Hospital, Columbus, Ohio

Keynote address
Genomic-phenomic data linkages to accelerate discovery in oncology: Obstacles and opportunities

Deborah Schrag, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion

David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York

Elaine R. Mardis

Deborah Schrag

Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening Reception
8:15-10 p.m.


Top of page


Friday, Jan. 10

Continental Breakfast
7-8 a.m.


Plenary Session 1: Machine Learning in Precision Oncology
Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
8-9:45 a.m.

The Treehouse Childhood Cancer Initiative
David Haussler, University of California, Santa Cruz, California

Drug predictive computational evaluations
Benjamin Haibe-Kains, Princess Margaret Cancer Centre, Toronto, ON, Canada

Clinical challenges in oncologic imaging: AI support from image analysis to integrated diagnostics
Evis Sala, University of Cambridge, Cambridge, United Kingdom

Panel Discussion

Break
9:45-10 a.m.


Plenary Session 2: Databases and EHRs
Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:45 a.m.

EHR-derived data platforms to advance precision medicine
Neal J. Meropol, Flatiron Health, New York, New York

Count me in: Partnering with patients to accelerate the pace of discoveries
Corrie Painter, Broad Institute of Harvard and MIT / CountMeIn, Cambridge, Massachusetts

Let’s make it easier to participate in research: A patient’s perspective
Liz Salmi, OpenNotes / Beth Israel Deaconess Medical Center, Boston, Massachusetts

Panel Discussion


Poster Session / Lunch (provided)
12-2:45 p.m.


Plenary Session 3: Panel Discussion on Real-World Evidence Generation, Payment Models, and Endpoints
Session Moderator: Elaine R. Mardis, Nationwide Children's Hospital, Columbus, Ohio
3-4:45 p.m.

Changing the care model
Lee Newcomer, Lee N. Newcomer Consulting, Wayzata, Minnesota

Building data and knowledge management systems to support precision medicine
Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, Massachusetts

Pillars of “personalized health care”
Levi A. Garraway, Genentech, South San Francisco, California

A platform approach to regulatory-grade RWE and outcomes validation
Jonathan Hirsch, Syapse, San Francisco, California

Panel Discussion


Dinner on Own / Free Time
4:45 p.m.

Top of page


Saturday, Jan. 11

Continental Breakfast
7-8 a.m.


Plenary Session 4: Novel Drug Development Approaches / Drugging Difficult Targets
Session Chair: David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York
8-9:45 a.m.

Acceleration of drug development through innovative trial design and strategy
José Baselga, AstraZeneca, Gaithersburg, Maryland

Title to be announced
Jeffrey A. Engelman, Novartis, Cambridge, Massachusetts

Challenging therapeutic targets: Categories and lessons learned
Levi A. Garraway, Genentech, South San Francisco, California

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 5: What Constitutes Adequate Screening?
Session Chair: Elaine R. Mardis, Nationwide Children's Hospital, Columbus, Ohio
10-11:45 a.m.

Discovery revisited: Challenges and opportunities in an age of clinical sequencing in oncology
Barry S. Taylor, Memorial Sloan Kettering Cancer Center, New York, New York

Longitudinal single cell DNA sequencing to reveal rare cancer cell populations and genome-phenome states in tumors
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Biomarkers and translational oncology in immuno-oncology
Alexandra Snyder, Merck & Co., Rahway, New Jersey

Panel Discussion


Lunch (provided) / Free Time
12-2 p.m.


Plenary Session 6: Unique Clinical Trial Designs
Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
2:15-4 p.m.

Title to be announced
J. Carl Barrett, AstraZeneca, Waltham, Massachusetts

The Drug Rediscovery protocol: Getting the most out of approved drugs
Emile E. Voest, Netherlands Cancer Institute, Amsterdam, Netherlands

Title to be announced
David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion


Dinner on Own / Free Time
4 p.m.


Top of page


Sunday, Jan. 12

Continental Breakfast
7:30-8:30 a.m.


Keynote Lecture
Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
8:30-9:10 a.m.

Large scale science in the private sector: The Story of Grail and the early detection of cancer
Richard D. Klausner, Lyell Immunopharma, South San Francisco, California


Plenary Session 7: Panel Discussion on Perspectives from Biotech and the Finance Sector
Moderators: J. Carl Barrett, AstraZeneca, Waltham, Massachusetts, and David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York
9:15-10:30 a.m.

Philip Dreyfuss, Farallon Capital, San Francisco, California

Thomas G. Roberts, Farallon Capital, San Francisco, California

James Tanenbaum, Foresite Capital, San Francisco, California

Alicia Zhou, Color Genomics, Burlingame, California


Break
10:30-10:45 a.m.


Plenary Session 8: MRD / Advanced Diagnostics
Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
10:45 a.m.-12:30 p.m.

Dissecting the biological and clinical underpinnings of immunotherapy resistance in the real world
Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts

Circulating tumor DNA as predictive biomarkers for response and toxicity with immunotherapy
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Circulating tumor DNA analysis for personalized cancer monitoring and detection
Maximilian Diehn, Stanford University, Stanford, California

Panel Discussion


Closing Remarks and Departure
12:30 p.m.


Top of page